Caxton Associates (New York)’s Elevance Health ELV Stock Holding History

Caxton Associates (New York)’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-657	Closed	-$323K	–	600
2022 Q1	$323K	Buy	+657	New	+$300K	0.03%	345
2021 Q4	–	Sell	-1,693	Closed	-$631K	–	584
2021 Q3	$631K	Buy	+1,693	New	+$643K	0.07%	164
2020 Q4	–	Sell	-1,595	Closed	-$428K	–	187
2020 Q3	$428K	Buy	1,595 +474	+42%	+$128K	0.05%	131
2020 Q2	$295K	Buy	+1,121	New	+$299K	0.03%	264
2019 Q4	–	Sell	-2,923	Closed	-$702K	–	434
2019 Q3	$702K	Buy	+2,923	New	+$801K	0.14%	80
2019 Q2	–	Sell	-1,853	Closed	-$532K	–	429
2019 Q1	$532K	Buy	+1,853	New	+$536K	0.08%	137
2018 Q2	–	Sell	-1,901	Closed	-$418K	–	402
2018 Q1	$418K	Buy	+1,901	New	+$447K	0.02%	277
2017 Q4	–	Sell	-3,100	Closed	-$589K	–	380
2017 Q3	$589K	Buy	+3,100	New	+$590K	0.02%	277

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

Caxton Associates (New York)'s ELV Position: Q2 2022 in Review

Caxton Associates (New York) sold out of Elevance Health (ELV) in Q2 2022, closing a stake of 657 shares — an estimated $323K sold.

Caxton Associates (New York) first reported a position in ELV in Q3 2017 and held it in 8 quarters. The position peaked at $702K in Q3 2019. 1,439 funds tracked by Wall St. Rank hold ELV as of Q2 2022.

Caxton Associates (New York) reported no remaining Elevance Health position as of Q2 2022 after selling out during the quarter.
Caxton Associates (New York) sold 657 Elevance Health shares in Q2 2022, an estimated $323K.
Caxton Associates (New York) first reported a position in Elevance Health in Q3 2017 and held it in 8 quarters.
Caxton Associates (New York)'s Elevance Health position peaked at $702K in Q3 2019.
1,439 funds tracked by Wall St. Rank held Elevance Health as of Q2 2022.

Based on Caxton Associates (New York)'s 13F filing for Q2 2022, filed 15 Aug 2022.